Extended-release morphine sulfate in treatment of severe acute and chronic pain
Andrea Trescot
Abstract
Open-access reader
Andrea Trescot
Abstract
Open-access reader
Abstract: Morphine is the archetypal opioid analgesic. Because it is a short-acting opioid, its use has been limited to the management of acute pain. The development of extended-release formulations have resulted in the increased utilization of morphine in chronic pain conditions. This review documents the history of morphine use in pain treatment, and describes the metabolism, pharmacodynamics, formulations, and efficacy of the currently available extended-release morphine medications. Keywords: Morphine ER, sustained-release morphine, MSContin, Oramorph ® , Kadian ® , Avinza ® , Embeda ®
OpenAlex reports 25 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Abstract: Morphine is the archetypal opioid analgesic. Because it is a short-acting opioid, its use has been limited to the management of acute pain. The development of extended-release formulations have resulted in the increased utilization of morphine in chronic pain conditions. This review documents the history of morphine use in pain treatment, and describes the metabolism, pharmacodynamics, formulations, and efficacy of the currently available extended-release morphine medications. Keywords: Morphine ER, sustained-release morphine, MSContin, Oramorph ® , Kadian ® , Avinza ® , Embeda ®
Key concepts: Medicine, Morphine sulfate, Morphine, Chronic pain, Acute pain, Anesthesia, Intensive care medicine, Pharmacology